RAVAGLIA, SABRINA MARIA
 Distribuzione geografica
Continente #
NA - Nord America 1.456
EU - Europa 1.252
AS - Asia 766
SA - Sud America 6
OC - Oceania 2
AF - Africa 1
Totale 3.483
Nazione #
US - Stati Uniti d'America 1.447
CN - Cina 601
IE - Irlanda 371
IT - Italia 252
UA - Ucraina 169
FI - Finlandia 166
SG - Singapore 146
DE - Germania 144
GB - Regno Unito 56
SE - Svezia 28
FR - Francia 19
BE - Belgio 17
CA - Canada 9
JP - Giappone 9
IN - India 8
NL - Olanda 7
CZ - Repubblica Ceca 5
BR - Brasile 4
CH - Svizzera 3
LU - Lussemburgo 3
ES - Italia 2
GR - Grecia 2
RU - Federazione Russa 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
CL - Cile 1
DK - Danimarca 1
HK - Hong Kong 1
KR - Corea 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
RO - Romania 1
Totale 3.483
Città #
Chandler 376
Dublin 368
Jacksonville 206
Nanjing 163
Boardman 117
Singapore 101
Ashburn 98
Helsinki 74
Beijing 72
Milan 61
Nanchang 60
Ann Arbor 52
Jiaxing 52
Lawrence 50
Princeton 50
Medford 49
Hebei 48
Changsha 46
Shenyang 41
Wilmington 41
Pavia 39
Shanghai 31
Hangzhou 30
New York 30
Tianjin 20
Brussels 17
Trieste 14
Verona 14
Bergamo 12
Los Angeles 12
Munich 12
Woodbridge 10
Frankfurt am Main 9
Tokyo 9
Toronto 9
Seattle 8
Turin 7
Gorlago 6
Kunming 6
Lodi 6
Modena 6
Norwalk 6
Pune 6
Bologna 5
Brno 5
Fairfield 5
Florence 5
Monza 5
Piscataway 5
Travaco Siccomario 5
Como 4
Dresden 4
Hanover 4
Naples 4
Rome 4
Washington 4
Amsterdam 3
Auburn Hills 3
Buccinasco 3
Cork 3
Dallas 3
Falkenstein 3
London 3
Saluzzo 3
San Francisco 3
Athens 2
Brembate di Sopra 2
Catania 2
Changchun 2
Charlotte 2
Des Moines 2
Esch-sur-Alzette 2
Jinan 2
Manfredonia 2
Udine 2
Vercelli 2
Villongo 2
Vimercate 2
Zhengzhou 2
Zurich 2
Alexandria 1
Altoona 1
Anápolis 1
Auckland 1
Bragado 1
Buffalo 1
Casalpusterlengo 1
Cesano Maderno 1
Chisinau 1
Cologno Monzese 1
Edinburgh 1
Fes 1
Fremont 1
Fuzhou 1
Guangzhou 1
Hong Kong 1
Houston 1
Jinhua 1
Krasnoyarsk 1
Lanzhou 1
Totale 2.580
Nome #
Mapping the human genetic architecture of COVID-19 164
A first update on mapping the human genetic architecture of COVID-19 92
Cognitive impairment and central motor conduction time in chronic alcoholics. 87
A Chaperone Enhances Blood α-Glucosidase Activity in Pompe Disease Patients Treated With Enzyme Replacement Therapy. 87
Enzyme replacement therapy (ERT) in adult-onset type II glycogenosis (GSDII) 86
Dietary treatment in adult-onset type II glycogenosis. 75
Recombinant alpha-glucosidase in adult-onset type II glycogenosis: The experience with the first Italian patient, from expanded access programmes to marketing authorization 75
The angiotensin-converting enzyme insertion/deletion polymorphysm modifies the clinical outcome in patients with Pompe disease. 73
Triggering migraine attacks:the role of nitroderivatives. 73
Severe recurrent myelitis in patients with hepatitis C virus infection 72
Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. 72
Clinical MRI dissociation in myelopathy: a clue to sarcoidosis? 72
Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant. 72
Emicrania emiplegica familiare: dalla genetica alla clinica. 71
Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encphalomyelitis. 69
Changes in nutritional status and body composition during enzyme replacementtherapy in adult-onset type II glycogenosis. 69
Pathogenetic role of myelitis for syringomyelia. 67
Efficacy of propafenone in paramyotonia congenita 66
Enzyme replacement therapy in adult-onset glycogenosis II: Is quantitative muscle MRI helpful? 65
Aspetti clinici e patogenetici della comorbidita’ emicranica. 65
Immune-mediated neuropathies in myeloma patients treated with bortezomib. 65
Combined central and peripheral demyelination: comparison of adult and pediatric series 64
Presyrinx in children with Chiari malformations 64
Early-onset ptosis in type II glycogenosis 62
Severe recurrent myelitis in patients with hepatitis C virus infection patients 61
Retinal migraine as unusual feature of cerebral autosomal dominantarteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL) 61
Outcome after Two Years of Enzyme Replacement Therapy (ERT) in 29 Patients with Late-Onset Type II Glycogenosis (GSDII) 60
Recombinant alglucosidase alpha (rhGAA) in adult-onset type II glycogenosis (GSDII): A follow-up study before and after treatment 59
NMO-IgG-negative relapsing myelitis 56
Strabismo parossistico: Meccanismi corticali e meccanismi periferici nella fisiopatologia di due casi con analoga fenomenologia critica 55
Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patientswith Alzheimer's disease and vascular dementia. 55
LOPED study: Looking for an early diagnosis in a late-onset Pompe disease high-risk population 54
Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease. 54
Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset Type II Glycogenosis? 53
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 53
RECOMBINANT ALGLUCOSIDASE ALFA IN ADULT-ONSET GLYCOGENOSIS TYPE II: A FOLLOW-UP STUDY BEFORE AND AFTER TREATMENT 50
Enzyme replacement therapy in severe adult-onset glycogen storage disease type II 50
Post-infectious inflammatory disordes:sub-groups based on prospective follow-up. 49
Bioimpedance Phase Angle as a Prognostic Tool in Late-Onset Pompe Disease: A Single-Centre Prospective Study With a 15-year Follow-Up 47
Enzyme replacement therapy in late-onset type II glycogenosis. 47
Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. 47
Erectile dysfunction as a sentinel symptom ofcardiovascular autonomic neuropathy in heavy drinkers 45
The diagnosis of migraine: clinical and instrumental aspects 45
Enzyme replacement therapy in adult-onset type II glycogenosis 45
Erratum: Spinal hemorrhage in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (Journal of Neurology (2014) 261 (438-440) DOI: 10.1007/s00415-013-7217-3) 45
Genotype-phenotype correlation in Pompe disease, a step forward. 44
Severe steroid-resistant post-infectious encephalomyelitis: General features and effects of IVIg 43
Ocular neuromyotonia with both tonic and paroxysmal components due to vascular compression 42
Diagnosis and therapy of acute disseminated encephalomyelitis and its variants 42
Guillain-Barré syndrome associated with SARS-CoV-2 41
Post-infectious and postvaccinal acute disseminated encephalomyelitis occurring in the same patients 41
COVID-19 in patients with Myasthenia Gravis: epidemiology and disease course 39
Adult-onset type II glycogenosis (GSDII): Clinical spectrum and enzyme replacement therapy (ERT) 38
null 34
ENZYME REPLACEMENT THERAPY IN LATE-ONSET PHENOTYPES OF GLYCOGENOSIS TYPE 2: RESULTS OF AN ITALIAN MULTICENTER STUDY 33
Familial hemiplegic migraine type 2 due to a novel missense mutation in ATP1A2 33
Trunk muscle involvement in late-onset Pompe disease: Study of thirty patients 32
HaNDL syndrome: a reversible cerebral vasoconstriction triggered by an infection? A case report and a case-based review 30
Enzyme replacement therapy in adult-onset glycogenosis II: Is quantitative muscle MRI helpful? 29
Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful? 28
Enzyme replacement therapy with Alglucosidase alfa in juvenile-adult glycogenosis type 2 patients 27
Distribution of Exonic Variants in Glycogen Synthesis and Catabolism Genes in Late Onset Pompe Disease (LOPD) 24
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 14
COVID-19 and Guillain-Barré syndrome: A single-center prospective case series with a 1-year follow-up 10
Mapping the human genetic architecture of COVID-19 3
Guillain‐Barré syndrome and COVID‐19: A 1‐year observational multicenter study 3
Totale 3.548
Categoria #
all - tutte 15.646
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.646


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020153 0 0 0 0 0 0 4 35 3 49 61 1
2020/2021284 39 29 6 33 3 39 2 44 6 40 36 7
2021/2022221 5 3 4 3 0 4 3 11 11 2 36 139
2022/20231.202 84 90 12 174 97 123 2 61 438 13 96 12
2023/2024398 49 73 11 18 28 102 5 26 5 10 19 52
2024/2025388 34 96 63 31 35 74 55 0 0 0 0 0
Totale 3.548